At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 128 enrolled
Drug / intervention
AZD0837 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Controlled, Randomized, Parallel , Multi-centre Feasibility Study of the Oral Direct Thrombin Inhibitor, AZD0837, Given as ER Formulation, in the Prevention of Stroke and Systolic Embolic Events in Patients With Atrial Fibrillation, Who Are Appropriate for But Unable/Unwilling to Take VKA Therapy
In Brief
A Phase 2 clinical trial evaluating AZD0837 and Aspirin for Persistent or Permanent Non-valvular Atrial Fibrillation. Completed, enrolled 128 participants across 38 sites in 6 countries.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Norway, Poland, Russia, Sweden, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedFeb 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedFeb 26, 2008
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.3 years ago
Interventions
AZD0837drug
ER formulation
Aspirindrug
Oral form